4.4 Review

Expanding the Role of Continuous Glucose Monitoring in Modern Diabetes Care Beyond Type 1 Disease

期刊

DIABETES THERAPY
卷 14, 期 8, 页码 1241-1266

出版社

SPRINGER HEIDELBERG
DOI: 10.1007/s13300-023-01431-3

关键词

Continuous glucose monitoring; Hospital inpatients; Pregnancy; Type 2 diabetes

向作者/读者索取更多资源

The application of continuous glucose monitoring (CGM) has revolutionized diabetes care by shifting from a reactive to proactive approach. CGM devices are now considered the gold standard for people with type 1 diabetes and evidence supports their use in type 2 diabetes as well. Expanding the use of CGM can lead to improved therapy, reduced complications, and lowered healthcare costs, all while enhancing quality of life for individuals with diabetes. Additionally, CGM can provide benefits for pregnant women with diabetes, non-diabetic individuals with glycemic dysregulation, and hospital inpatients.
Application of continuous glucose monitoring (CGM) has moved diabetes care from a reactive to a proactive process, in which a person with diabetes can prevent episodes of hypoglycemia or hyperglycemia, rather than taking action only once low and high glucose are detected. Consequently, CGM devices are now seen as the standard of care for people with type 1 diabetes mellitus (T1DM). Evidence now supports the use of CGM in people with type 2 diabetes mellitus (T2DM) on any treatment regimen, not just for those on insulin therapy. Expanding the application of CGM to include all people with T1DM or T2DM can support effective intensification of therapies to reduce glucose exposure and lower the risk of complications and hospital admissions, which are associated with high healthcare costs. All of this can be achieved while minimizing the risk of hypoglycemia and improving quality of life for people with diabetes. Wider application of CGM can also bring considerable benefits for women with diabetes during pregnancy and their children, as well as providing support for acute care of hospital inpatients who experience the adverse effects of hyperglycemia following admission and surgical procedures, as a consequence of treatment-related insulin resistance or reduced insulin secretion. By tailoring the application of CGM for daily or intermittent use, depending on the patient profile and their needs, one can ensure the cost-effectiveness of CGM in each setting. In this article we discuss the evidence-based benefits of expanding the use of CGM technology to include all people with diabetes, along with a diverse population of people with non-diabetic glycemic dysregulation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据